Co-Authors
This is a "connection" page, showing publications co-authored by David Montefiori and Barton Haynes.
Connection Strength
3.939
-
Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies. Cell. 2021 05 27; 184(11):2955-2972.e25.
Score: 0.237
-
Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses. Nature. 2021 06; 594(7864):553-559.
Score: 0.236
-
Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates. NPJ Vaccines. 2021 Apr 09; 6(1):50.
Score: 0.235
-
SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. Cell Host Microbe. 2021 04 14; 29(4):529-539.e3.
Score: 0.233
-
D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization. Cell Host Microbe. 2021 01 13; 29(1):23-31.e4.
Score: 0.229
-
Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal Models. Cell Rep. 2017 12 26; 21(13):3681-3690.
Score: 0.187
-
HIV DNA-Adenovirus Multiclade Envelope Vaccine Induces gp41 Antibody Immunodominance in Rhesus Macaques. J Virol. 2017 11 01; 91(21).
Score: 0.184
-
Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge. Nat Commun. 2017 06 08; 8:15711.
Score: 0.180
-
HIV-1 Consensus Envelope-Induced Broadly Binding Antibodies. AIDS Res Hum Retroviruses. 2017 08; 33(8):859-868.
Score: 0.180
-
Staged induction of HIV-1 glycan-dependent broadly neutralizing antibodies. Sci Transl Med. 2017 03 15; 9(381).
Score: 0.177
-
Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide. Sci Transl Med. 2017 03 15; 9(381).
Score: 0.177
-
Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates. Cell Rep. 2017 02 28; 18(9):2175-2188.
Score: 0.177
-
Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial. PLoS Pathog. 2017 02; 13(2):e1006182.
Score: 0.176
-
Potent and broad HIV-neutralizing antibodies in memory B cells and plasma. Sci Immunol. 2017 Jan 27; 2(7).
Score: 0.175
-
Antibody-virus co-evolution in HIV infection: paths for HIV vaccine development. Immunol Rev. 2017 01; 275(1):145-160.
Score: 0.175
-
Immune perturbations in HIV-1-infected individuals who make broadly neutralizing antibodies. Sci Immunol. 2016 Jul 29; 1(1):aag0851.
Score: 0.170
-
In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. Cell. 2021 08 05; 184(16):4203-4219.e32.
Score: 0.059
-
Cold sensitivity of the SARS-CoV-2 spike ectodomain. Nat Struct Mol Biol. 2021 02; 28(2):128-131.
Score: 0.058
-
HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design. Cell Host Microbe. 2019 08 14; 26(2):296.
Score: 0.052
-
Characterization of HIV-1 Nucleoside-Modified mRNA Vaccines in Rabbits and Rhesus Macaques. Mol Ther Nucleic Acids. 2019 Apr 15; 15:36-47.
Score: 0.051
-
Tracking HIV-1 recombination to resolve its contribution to HIV-1 evolution in natural infection. Nat Commun. 2018 05 15; 9(1):1928.
Score: 0.048
-
Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. J Exp Med. 2018 06 04; 215(6):1571-1588.
Score: 0.048
-
Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant. PLoS One. 2018; 13(4):e0194266.
Score: 0.048
-
Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial. J Infect Dis. 2018 03 28; 217(8):1280-1288.
Score: 0.048
-
HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees. J Virol. 2018 04 15; 92(8).
Score: 0.048
-
HIV-1-Specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galactosylceramide Blocking and Phagocytosis. J Virol. 2018 04 01; 92(7).
Score: 0.047
-
Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge. J Virol. 2018 01 15; 92(2).
Score: 0.047
-
HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine. J Virol. 2017 12 15; 91(24).
Score: 0.047
-
HIV transmitted/founder vaccines elicit autologous tier 2 neutralizing antibodies for the CD4 binding site. PLoS One. 2017; 12(10):e0177863.
Score: 0.046
-
Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women. PLoS One. 2017; 12(5):e0176428.
Score: 0.045
-
Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting. PLoS Pathog. 2017 01; 13(1):e1006148.
Score: 0.044
-
Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection. EBioMedicine. 2016 12; 14:97-111.
Score: 0.043
-
Comparison of viral Env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design. J Virol. 2013 Jul; 87(13):7218-33.
Score: 0.034